Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immucell Corp (ICCC)

Immucell Corp (ICCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immucell Corp 56 EVERGREEN DR PORTLAND ME 04103 USA

www.immucell.com Employees: 75 P: 207-878-2770

Sector:

Medical

Description:

ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibodytechnology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea.

Key Statistics

Overview:

Market Capitalization, $K 53,552
Enterprise Value, $K 60,332
Shares Outstanding, K 9,046
Annual Sales, $ 26,490 K
Annual Net Income, $ -2,160 K
Last Quarter Sales, $ 5,510 K
Last Quarter Net Income, $ -140 K
EBIT, $ 2,330 K
EBITDA, $ 5,060 K
60-Month Beta 0.18
% of Insider Shareholders 5.60%
% of Institutional Shareholders 13.47%
Float, K 8,539
% Float 94.40%
Short Interest 15
Short Float 0.17%
Short Volume Ratio 0.29

Growth:

1-Year Return 15.34%
3-Year Return -14.46%
5-Year Return 1.44%
5-Year Revenue Growth 93.08%
5-Year Earnings Growth -36.84%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 11/13/25
Next Earnings Date 02/24/26
Earnings Per Share ttm 0.26
EPS Growth vs. Prev Qtr -133.33%
EPS Growth vs. Prev Year 77.78%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-2 on 12/23/04

ICCC Ratios

Ratio
Price/Earnings ttm 23.65
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 8.00%
Return-on-Assets % 5.07%
Profit Margin % -8.15%
Debt/Equity 0.32
Price/Sales 2.06
Price/Cash Flow 95.65
Price/Book 1.87
Book Value/Share 3.29
Interest Coverage -0.62
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar